Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684540 | 1.00 | FABP5 (0.49) | FABP5FABP7KMT2AEPHX2SRR | |
| SCHEMBL14332667 | 0.91 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2SRR | |
| SCHEMBL9117856 | 0.88 | EPHX2 (0.55) | FABP5FABP7KMT2AEPHX2MDM4 | |
| SCHEMBL7198855 | 0.87 | KMT2A (0.44) | FABP5FABP7KMT2AEPHX2SRR | |
| SCHEMBL1827402 | 0.85 | FOLH1 (0.46) | FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL1827404 | 0.85 | FOLH1 (0.46) | FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL9660107 | 0.84 | CYP1A2 (0.53) | FABP5FABP7KMT2AEPHX2MDM4 | |
| SCHEMBL1162471 | 0.84 | KMT2A (0.55) | FABP5FABP7KMT2AEPHX2MDM4 | |
| SCHEMBL1829604 | 0.84 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2MDM4 | |
| SCHEMBL1829602 | 0.84 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2010093849-A2 | PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | FABP5 1490/4885FABP7 2466/4885KMT2A 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.